Biogen Inc (NASDAQ: BIIB) has a price-to-earnings ratio that is above its average at 13.55x. The stock has a 36-month beta value of -0.07. Opinions on the stock are mixed, with 13 analysts rating it as a “buy,” 6 as “overweight,” 16 as “hold,” and 0 as “sell.”
The public float for BIIB is 144.68M, and at present, short sellers hold a 1.78% of that float. On January 03, 2025, the average trading volume of BIIB was 1.52M shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
BIIB) stock’s latest price update
Biogen Inc (NASDAQ: BIIB)’s stock price has decreased by -1.91 compared to its previous closing price of 152.92. However, the company has seen a 0.66% increase in its stock price over the last five trading sessions. zacks.com reported 2025-01-01 that The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here’s why you should take advantage.
BIIB’s Market Performance
Biogen Inc (BIIB) has seen a 0.66% rise in stock performance for the week, with a -8.66% decline in the past month and a -20.53% plunge in the past quarter. The volatility ratio for the week is 2.23%, and the volatility levels for the past 30 days are at 2.37% for BIIB. The simple moving average for the last 20 days is -1.58% for BIIB stock, with a simple moving average of -24.55% for the last 200 days.
Analysts’ Opinion of BIIB
BMO Capital Markets, on the other hand, stated in their research note that they expect to see BIIB reach a price target of $164, previously predicting the price at $230. The rating they have provided for BIIB stocks is “Market Perform” according to the report published on December 20th, 2024.
Stifel gave a rating of “Hold” to BIIB, setting the target price at $175 in the report published on December 16th of the previous year.
BIIB Trading at -7.75% from the 50-Day Moving Average
After a stumble in the market that brought BIIB to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -44.09% of loss for the given period.
Volatility was left at 2.37%, however, over the last 30 days, the volatility rate increased by 2.23%, as shares sank -6.75% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -18.77% lower at present.
During the last 5 trading sessions, BIIB rose by +0.66%, which changed the moving average for the period of 200-days by -31.63% in comparison to the 20-day moving average, which settled at $152.40. In addition, Biogen Inc saw -1.91% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at BIIB starting from Singhal Priya, who sale 110 shares at the price of $157.21 back on Dec 09 ’24. After this action, Singhal Priya now owns 5,426 shares of Biogen Inc, valued at $17,293 using the latest closing price.
Singhal Priya, the Officer of Biogen Inc, proposed sale 110 shares at $157.21 during a trade that took place back on Dec 09 ’24, which means that Singhal Priya is holding shares at $17,293 based on the most recent closing price.
Stock Fundamentals for BIIB
Current profitability levels for the company are sitting at:
- 0.21 for the present operating margin
- 0.72 for the gross margin
The net margin for Biogen Inc stands at 0.17. The total capital return value is set at 0.09. Equity return is now at value 10.47, with 5.72 for asset returns.
Based on Biogen Inc (BIIB), the company’s capital structure generated 0.28 points at debt to capital in total, while cash flow to debt ratio is standing at 0.34. The debt to equity ratio resting at 0.38. The interest coverage ratio of the stock is 7.59.
Currently, EBITDA for the company is 2.38 billion with net debt to EBITDA at 1.71. When we switch over and look at the enterprise to sales, we see a ratio of 2.85. The receivables turnover for the company is 4.73for trailing twelve months and the total asset turnover is 0.33. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.26.
Conclusion
To sum up, Biogen Inc (BIIB) has seen a bad performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
